Contact
searchSearch
HMP Global
Login

Acute Myeloid Leukemia Excellence Forum

Acute Myeloid Leukemia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Amer Zeidan, MBBS, MHS
Conference Coverage
Ziftomenib Plus Standard Induction Therapy Demonstrates Meaningful Clinical Activity for Patients With AML: KOMET-007
08/25/2025
Amer Zeidan, MBBS
At the EHA 2025 Congress, Amer Zeidan, MBBS, MHS, shared results from the KOMET-007 trial which evaluated the efficacy of ziftomenib combined with standard induction therapy for patients with newly diagnosed acute myeloid leukemia.
At the EHA 2025 Congress, Amer Zeidan, MBBS, MHS, shared results from the KOMET-007 trial which evaluated the efficacy of ziftomenib combined with standard induction therapy for patients with newly diagnosed acute myeloid leukemia.
At the EHA 2025 Congress, Amer...
08/25/2025
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML
08/20/2025
Amer Zeidan, MBBS
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares...
08/20/2025
Oncology
Naval Daver, MD
Conference Coverage
Challenges of Applying MRD Decision-Making to Determine Transplant Among Patients With AML
08/05/2025
Naval G. Daver
At the 2025 Great Debates in Hematologic Malignancies meeting, Naval Daver, MD, debates against minimal residual disease negativity as the predominate determining factor for transplant eligibility among patients with acute myeloid leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting, Naval Daver, MD, debates against minimal residual disease negativity as the predominate determining factor for transplant eligibility among patients with acute myeloid leukemia.
At the 2025 Great Debates in...
08/05/2025
Oncology
Aaron Goldberg, MD, PhD
Conference Coverage
Optimizing Targeted and Genetic Therapeutic Strategies for Patients With R/R Acute Myeloid Leukemia
08/05/2025
At the 2025 Great Debates in Hematologic Malignancies meeting, Aaron Goldberg, MD, PhD, discussed evolving treatment strategies and therapies for patients with relapsed/ refractory acute myeloid leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting, Aaron Goldberg, MD, PhD, discussed evolving treatment strategies and therapies for patients with relapsed/ refractory acute myeloid leukemia.
At the 2025 Great Debates in...
08/05/2025
Oncology
Andrew Artz, MD, MS
Conference Coverage
Benefits of Utilizing MRD Negativity to Determine Transplant Eligibility for Patients With AML
08/05/2025
Andrew Artz, MD, MS, participated in a debate arguing for the benefits of utilizing minimal residual disease negativity as the primary marker for transplantation eligibility among patients with acute myeloid leukemia at the 2025 Great Debates...
Andrew Artz, MD, MS, participated in a debate arguing for the benefits of utilizing minimal residual disease negativity as the primary marker for transplantation eligibility among patients with acute myeloid leukemia at the 2025 Great Debates...
Andrew Artz, MD, MS,...
08/05/2025
Oncology
Sangeetha Venugopal, MD
Videos
Utilizing Menin Inhibitor Therapy for Patients With Relapsed Acute Myeloid Leukemia
02/08/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Sangeetha Venugopal, MD, discusses considerations for utilizing menin inhibitor therapy for patients with relapsed AML.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Sangeetha Venugopal, MD, discusses considerations for utilizing menin inhibitor therapy for patients with relapsed AML.
At the 2025 Lymphoma, Leukemia &...
02/08/2025
Oncology
Areej El-Jawahri, MD, Massachusetts General Hospital
Conference Coverage
Palliative Care vs Standard of Care in Discussion of End-of-Life Care Preferences for Patients With AML and MDS
06/01/2024

Featuring Areej El-Jawahri, MD

Featuring Areej El-Jawahri, MD ...
Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...
Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...
Areej El-Jawahri MD, discusses...
06/01/2024
Oncology
Jessica Altman, MD
Conference Coverage
Sequential Therapy vs Triplet Therapy for Patients With Newly Diagnosed AML Ineligible for Intensive Chemotherapy
04/09/2024

Featuring Jessica Altman, MD

Featuring Jessica Altman, MD
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...
During the 2024 Great Debates &...
04/09/2024
Oncology
Talha Badar, MD
Conference Coverage
Hypomethylating Agent Monotherapy Compared With Hypomethylating Agent Plus Venetoclax Regimen Among Patients With Untreated TP53-Mutated AML
01/03/2024
Talha Badar, MD
At the 65th ASH Annual Meeting, Talha Badar, MD, discusses a retrospective study on the efficacy of venetoclax combined with hypomethylating agent (HMA) therapy vs HMA monotherapy for patients with TP53-mutated acute myeloid leukemia.
At the 65th ASH Annual Meeting, Talha Badar, MD, discusses a retrospective study on the efficacy of venetoclax combined with hypomethylating agent (HMA) therapy vs HMA monotherapy for patients with TP53-mutated acute myeloid leukemia.
At the 65th ASH Annual Meeting,...
01/03/2024
Oncology
Sylvain Garciaz, MD
Conference Coverage
Long-Term Survival Rates and Discontinuation of Venetoclax/Azacitidine for Responding Patients With AML
12/15/2023
Sylvain Garciaz, MD
At the 65th ASH Annual Meeting, Sylvain Garciaz, MD, shared insights on the potential benefit of stopping venetoclax and/or azacytidine treatment for responding patients with acute myeloid leukemia.
At the 65th ASH Annual Meeting, Sylvain Garciaz, MD, shared insights on the potential benefit of stopping venetoclax and/or azacytidine treatment for responding patients with acute myeloid leukemia.
At the 65th ASH Annual Meeting,...
12/15/2023
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use